Still hope on Kintor due to the new announcement
    Treatment 12/20/2023

    At a glance
    In this general discussion post, the primary subjects mentioned are the tone is 😐 neutral.

    Other terms

    The conversation is about Kintor's announcement indicating continued hope for their product KX-826 as a treatment for Alopecia Androgenetica. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.
    View this post in the Community →

    Similar Community Posts Join

    5 / 189 results

      community Received Kintor’s KX-826 Today

      in Product  84 upvotes 3 months ago
      A user received Kintor’s KX-826/Pyrilutamide and shared initial impressions, noting concerns about the product's labeling and marketing. Other users discussed the legitimacy of the product, its effectiveness, and compared it to other treatments like Minoxidil and Finasteride.

      community KX-826: Long-Term Safety Results are out!

      in Research/Science  158 upvotes 1 month ago
      KX-826 initially improves hair growth but declines after 24 weeks, with mild itching as a side effect. Combining it with minoxidil and finasteride may improve results, but long-term effectiveness is uncertain.

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  136 upvotes 7 months ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

      community Pyrilutamide Phase 3 on its way

      in Treatment  127 upvotes 2 years ago
      Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.

    Related Research

    6 / 125 results